As the life science industry left 2020 behind, it joined a new trend: going public through a mechanism that combines an IPO and merger in one transaction.
Upon completion of the merger, which will value 23andMe at $3.5 billion, Virgin Group Acquisition Corp. will change its New York Stock Exchange ticker symbol to ME.
The move raises questions about what precisely is an LDT outside of FDA jurisdiction and heightens concerns that poorly validated tests will enter the market and endanger public health.
A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.
Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.
